Quick Answer
Organogenesis Holdings Inc. reported Cash and Equivalents of $93.68 million for fiscal year 2025.
Organogenesis Holdings Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $93.68M | -30.9% |
| 2024 | $135.57M | +30.6% |
| 2023 | $103.84M | +1.3% |
| 2022 | $102.48M | -10.1% |
| 2021 | $113.93M | +35.0% |
| 2020 | $84.39M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $63.74M | -32.4% | -12.8% |
| June 30, 2025 | $73.08M | -18.7% | -33.5% |
| March 31, 2025 | $109.97M | +24.1% | -18.9% |
| December 31, 2024 | $135.57M | +30.6% | +43.7% |
| September 30, 2024 | $94.34M | -4.0% | +4.9% |
| June 30, 2024 | $89.90M | +1.1% | +1.4% |
| March 31, 2024 | $88.63M | -0.1% | -14.7% |
| December 31, 2023 | $103.84M | +1.3% | +5.7% |
- Organogenesis Holdings Inc. showed a decrease of -30.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Organogenesis Holdings Inc.’s cash and equivalents has grown by 11.0% (from $84.39 million to $93.68 million).
- The most recent figure is from Organogenesis Holdings Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: